论文部分内容阅读
目的:探讨参芪扶正注射液联合化疗治疗原发性肝癌、改善化疗不良反应的作用。方法:本研究采用前瞻性开放性病例对照研究,将74例肝癌患者随机分为治疗组(38例)和对照组(36例)。对照组采用肝癌CAFI化疗方案(顺铂20mg/M2IVD第1-4天,阿霉素40mg/M2IV第1天,氟尿嘧啶400mg/M2IV第1-4天,干扰素50wu/M2SC第1-4天;28天为1个周期;治疗组在CAFI化疗方案基础上加用参芪扶正注射液250mL静脉滴注,每天1次,28天为1个周期。两组患者均用药2个周期;观察近期疗效、生活质量变化、不良反应及免疫功能变化。结果:治疗2个周期后,治疗组患者在疗效控制情况、生活质量Karnofsky评分、不良反应与对照组比均明显改善(P<0.01)。结论:参芪扶正注射液联合化疗治疗原发性肝癌,可提高疗效,改善生活质量,减轻化疗的毒副反应。
Objective: To investigate the effect of Shenqi Fuzheng injection combined with chemotherapy in the treatment of primary liver cancer and improve the adverse reaction of chemotherapy. Methods: A prospective, open case-control study was conducted in this study. Totally 74 patients with HCC were randomly divided into treatment group (38 cases) and control group (36 cases). The control group received chemotherapy with liver cancer CAFI (cisplatin 20mg / M2IVD day 1-4, doxorubicin 40mg / M2IV day 1, fluorouracil 400mg / M2IV day 1-4, interferon 50wu / M2SC day 1-4; 28 days for a cycle; the treatment group on the basis of the CAFI chemotherapy plus Shenqi Fuzheng injection 250mL intravenous infusion, once a day, 28 days for a cycle of two groups were treated with two cycles; observed short-term efficacy , Quality of life changes, adverse reactions and changes in immune function.Results: After 2 cycles of treatment, the patients in the treatment group were significantly improved in efficacy control, quality of life Karnofsky score, adverse reactions and the control group (P0.01) .Conclusion: Shenqi Fuzheng injection combined with chemotherapy for the treatment of primary liver cancer, can improve the curative effect, improve the quality of life, reduce the side effects of chemotherapy.